Ibrutinib’s off-target mechanism: cause for dose optimization-Reference-Cited by-同舟云学术

Ibrutinib’s off-target mechanism: cause for dose optimization

Published:2021-10-10 Issue:10-12 Volume:22 Page:529-531
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Zimmerman Sara M.¹^ORCID,Peer Cody J.¹,Figg William D.¹

Affiliation:

1. Clinical Pharmacology Program, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Funder

National Institutes of Health

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2021.1980313

Reference24 articles.

1. Imbruvica: leading the way with a wave of evidence. [accessed 2021 Mar 25]. https://imbruvicahcp.com.

2. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

3. Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study

4. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

5. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis;Annals of Hematology;2024-08-17

2. Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis;2024-06-06

3. Oral Oncolytics and Cardiovascular Risk Management and Monitoring;Journal of Cardiovascular Pharmacology;2023-10

4. Repurposing ibrutinib: therapeutic effects and implications for translational approaches in Alzheimer’s disease;Neural Regeneration Research;2023

5. Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice;International Journal of Molecular Sciences;2022-11-03